ICU sedation, delirium & recovery
Association Between Protocolized Magnesium Supplementation and Atrial Fibrillation or Flutter in Critically Ill Patients: A Multicenter Retrospective Cohort Study
Authors' conclusion
Protocolized magnesium supplementation at a threshold of 0.95 mmol/L (2.31 mg/dL) may be associated with reduced 24-hour incidence of atrial fibrillation and flutter in critically ill patients.
Study context
- Population
- Adults admitted to ICU with a magnesium protocol order, first magnesium level 0.92–0.99 mmol/L, 5 hospitals in Ontario, Canada, 2022–2024
- Participants
- 4,198 adults
- Exposure
- Protocolized magnesium supplementation vs no supplementation
- Supplementationn = 2,144
- No supplementationn = 2,054reference
- Outcome
- Atrial fibrillation or flutter
- Follow-up
- 24 hours
Methodological detailspseudo-randomised, multicentre, Bayesian logistic regression adjusted for hospital
- Pseudo-randomised
- Multicentre
- Bayesian logistic regression adjusted for hospital
Main finding
As reported in the abstract
Absolute risk reduction
1.6%
95% CrI 3.8% reduction to 0.8% increase
Events by group
Observational data: associations, not effects.
Secondary outcomes
| Outcome | Absolute risk reduction (CrI) |
|---|---|
| Composite of AF and flutter, tachyarrhythmia, and death · 24 hoursProbability of risk reduction, 0.97 · CrI | 2.2% (4.3% reduction to 0.1% increase) |
Original publication
Association Between Protocolized Magnesium Supplementation and Atrial Fibrillation or Flutter in Critically Ill Patients: A Multicenter Retrospective Cohort Study. Crit Care Med. Published 30 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →